- Home
- BKYI vs BIAF Comparison
BKYI vs BIAF Comparison
Compare BKYI & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKYI | BIAF |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 6.8M |
| IPO Year | 1997 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BKYI | BIAF |
|---|---|---|
| Price | $0.58 | $1.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 278.2K | 74.4K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,316,050.00 | ★ $6,776,739.00 |
| Revenue This Year | $7.45 | N/A |
| Revenue Next Year | $23.29 | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.53 | $1.11 |
| 52 Week High | $3.68 | $46.53 |
Technical Indicators
Market Signals| Indicator | BKYI | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 36.15 |
| Support Level | $0.53 | $1.11 |
| Resistance Level | $0.63 | $1.37 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 21.48 | 19.03 |
Price Performance
Historical ComparisonAbout BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.